BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Clinical trial NCT02834364 · COMPLETED

Trial details

NCT number: NCT02834364
Sponsor: University of Heidelberg Medical Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed or Refractory Multiple Myeloma Patients With BRAFV600 E or BRAFV600K Mutation

Start date: 2016-06-01
Primary completion: 2023-03-29
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.